Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 29, 2012, Pages 11663-11668

  Ehmann, David E ^a   Jahić, Haris ^a   Ross, Philip L ^a   Gu, Rong Fang ^a   Hu, Jun ^a   Kern, Gunther ^a   Walkup, Grant K ^a   Fisher, Stewart L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antibacterial; Drug discovery; Enzymology

Indexed keywords

AVIBACTAM; BETA LACTAMASE TEM 1;

ACYLATION; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DEACYLATION; DRUG MECHANISM; ENZYME ACTIVITY; HYDROLYSIS; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGENERATION;

ACYLATION; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; DRUG DISCOVERY; GRAM-NEGATIVE BACTERIAL INFECTIONS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 84863905057     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205073109     Document Type: Article

References (39)

1. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med 360:439-443.
2. Nordmann P, Poirel L, Toleman MA, Walsh TR (2011) Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 66:689-692.
3. Bush K, Jacoby GA (2010) Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969-976.
4. Bush K, Fisher JF (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 65:455-478.
5. Bebrone C, et al. (2010) Current challenges in antimicrobial chemotherapy: Focus on β-lactamase inhibition. Drugs 70:651-679.
6. Biondi S, Long S, Panunzio M, Qin WL (2011) Current trends in β-lactam based β-lactamases inhibitors. Curr Med Chem 18:4223-4236.
7. Fisher JF, Meroueh SO, Mobashery S (2005) Bacterial resistance to beta-lactam antibiotics: Compelling opportunism, compelling opportunity. Chem Rev 105:395-424. (Pubitemid 40351628)
8. Fisher JF, Mobashery S (2009) Three decades of the class A β-lactamase acyl-enzyme. Curr Protein Pept Sci 10:401-407.
9. Coleman K (2011) Diazabicyclooctanes (DBOs): A potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 14:550-555.
10. Morrison JF, Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
11. Fersht A (1985) Enzyme Structure and Mechanism (Freeman, New York), pp 140-141.
12. Copeland RA, Basavapathruni A, Moyer M, Scott MP (2011) Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Anal Biochem 416:206-210.
13. Brown RP, Aplin RT, Schofield CJ (1996) Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: Observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35:12421-12432. (Pubitemid 26318037)
14. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y (1993) Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 37:851-858. (Pubitemid 23096890)
15. Bonnefoy A, et al. (2004) In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J Antimicrob Chemother 54:410-417. (Pubitemid 39177462)
16. Stachyra T, et al. (2010) Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob Agents Chemother 54:5132-5138.
17. Yang Y, et al. (2000) Mechanism of inhibition of the class A β-lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry. J Biol Chem 275:26674-26682.
18. Tabei K, et al. (2004) Mechanism of inactivation of β-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry. J Med Chem 47:3674-3688. (Pubitemid 38822028)
19. Martin R, Gold M, Jones JB (1994) Inhibition of the RTEM-1 β-lactamase by boronic acids. Bioorg Med Chem Lett 4:1229-1234. (Pubitemid 24164203)
20. De Meester F, et al. (1987) Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem Pharmacol 36:2393-2403. (Pubitemid 17097419)
21. Christensen H, Martin MT, Waley SG (1990) β-lactamases as fully efficient enzymes. Determination of all the rate constants in the acyl-enzyme mechanism. Biochem J 266: 853-861. (Pubitemid 20103722)
22. De Meester F, et al. (1986) 6-β-Iodopenicillanate as a probe for the classification of β-lactamases. Biochem J 239:575-580.
23. Bulychev A, et al. (1995) Potent mechanism-based inhibition of the TEM-1 β-lactamase by novel N-sulfonyloxy β-lactams. J Am Chem Soc 117:5938-5943.
24. Charnas RL, Knowles JR (1981) Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid. Biochemistry 20:2732-2737. (Pubitemid 11038334)
25. Matagne A, Ghuysen MF, Frère JM (1993) Interactions between active-site-serine β-lactamases and mechanism-based inactivators: A kinetic study and an overview. Biochem J 295:705-711.
26. Pitarch J, Ruiz-Lopez MF, Silla E, Pascual-Ahuir J, Tunon I (1998) Neutral and alkaline hydrolysis of model β-lactam antibiotics. An ab initio study of water catalysis. J Am Chem Soc 120:2146-2155. (Pubitemid 28179186)
27. Powers JC, Asgian JL, Ekici OD, James KE (2002) Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 102:4639-4750.
28. Long JZ, Cravatt BF (2011) The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev 111:6022-6063.
29. Ahn K, et al. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46:13019-13030. (Pubitemid 350086220)
30. Westwood NJ, Claridge TDW, Edwards PN, Schofield CJ (1997) Reversible acylation of elastase by gamma-lactam analogs of β-lactam inhibitors. Bioorg Med Chem Lett 7:2973-2978. (Pubitemid 27519570)
31. Garvey EP (2010) Structural mechanisms of slow-onset, two-step enzyme inhibition. Curr Chem Biol 4:64-73.
32. Fieulaine S, et al. (2011) Trapping conformational states along ligand-binding dynamics of peptide deformylase: The impact of induced fit on enzyme catalysis. PLoS Biol 9:e1001066.
33. Lu H, Tonge PJ (2010) Drug-target residence time: Critical information for lead optimization. Curr Opin Chem Biol 14:467-474.
34. Copeland RA (2010) The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 5:305-310.
35. Endimiani A, et al. (2011) Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:82-85.
36. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP (2011) In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended- spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:3220-3225.
37. Lucasti C, Popescu I, Ramesh M, Lipka J, Sable C (2011) Efficacy and safety of ceftazidime/ NXL104 plus metronidazole vs. meropenem in the treatment of complicated intra-abdominal infections in hospitalised adults. Clin Microbiol Infect 17:S437.
38. Vazquez J, Gonzalez Patzan LD, Lipka J, Sable C (2011) Efficacy, safety and tolerability of ceftazidime/NXL104 vs. imipenem cilastatin in the treatment of complicated urinary tract infections in hospitalised adults. Clin Microbiol Infect 17:S438.
39. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery (Wiley, New York), pp 179-185.